ASND vs NVO
ASND: Ascendis Pharma is a biopharma company leveraging its proprietary TransCon technology platform to develop best-in-class therapies for endocrine rare diseases and large-market conditions. NVO: A global healthcare leader specializing in innovative treatments for diabetes, obesity, and other serious chronic conditions.
Side-by-side fundamentals
| Metric | ASND | NVO | Edge |
|---|---|---|---|
| Price as of 2026-10-21 close | $238.90 | $39.06 | |
| Market cap as of 2025-12-31 (share count; price 2026-10-21) | n/a | $173.6B | |
| Net margin FY2025, SEC XBRL | n/a | +33.1% | |
| Gross margin FY2025, SEC XBRL | n/a | +81.0% | |
| Operating margin FY2025, SEC XBRL | n/a | +41.3% | |
| ROE FY2025, SEC XBRL | n/a | +52.8% | |
| ROA FY2025, SEC XBRL | n/a | +18.9% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +20.4% | |
| Dividend yield as of 2026-09-03 | n/a | +2.7% | |
| Beta | 0.38 | 0.82 | |
| 1-year return as of 2026-10-21 close | +19.1% | -28.7% | ASND higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.